James Scibetta
Director/Board Member at MATINAS BIOPHARMA HOLDINGS, INC.
Net worth: 106 593 $ as of 30/05/2024
Profile
James S.
Scibetta is currently the Chief Executive Officer & Director at Maverick Therapeutics, Inc., ImmuneID, Inc., and an Independent Director at Matinas BioPharma Holdings, Inc. He previously served as Chairman at Nephros, Inc., Director at Labopharm, Inc., Chief Financial Officer at Bioenvision, Inc., and Chief Financial Officer & Executive Vice President at Merrimack Pharmaceuticals, Inc. He was also the President at Pacira Biosciences, Inc. from 2016 to 2017 and an Independent Director at Aquestive Therapeutics, Inc. from 2017 to 2022.
Scibetta received his undergraduate degree from Wake Forest University and his MBA from the University of Michigan.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 17/03/2024 | 649,958 ( 0.26% ) | 106 593 $ | 30/05/2024 |
James Scibetta active positions
| Companies | Position | Start |
|---|---|---|
| MATINAS BIOPHARMA HOLDINGS, INC. | Director/Board Member | 31/10/2013 |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Chief Executive Officer | 31/12/2016 |
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Chief Executive Officer | 20/09/2021 |
Former positions of James Scibetta
| Companies | Position | End |
|---|---|---|
| AQUESTIVE THERAPEUTICS, INC. | Director/Board Member | 21/06/2022 |
| PACIRA BIOSCIENCES, INC. | Director of Finance/CFO | 02/05/2016 |
| NEPHROS, INC. | Chairman | 30/12/2013 |
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Director/Board Member | 06/11/2008 |
Bioenvision, Inc.
 Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Director of Finance/CFO | 31/10/2007 |
Training of James Scibetta
| Wake Forest University | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| NEPHROS, INC. | Health Technology |
| PACIRA BIOSCIENCES, INC. | Health Technology |
| MATINAS BIOPHARMA HOLDINGS, INC. | Health Technology |
| AQUESTIVE THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
Merrimack Pharmaceuticals, Inc.
 Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Bioenvision, Inc.
Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Health Services |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Health Technology |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |
- Stock Market
- Insiders
- James Scibetta
